文献速递类风湿关节炎

甲氨蝶呤对依那西普治疗的类风湿关节炎患者肿瘤坏死因子浓度的影响

The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究在186例连续接受依那西普治疗的类风湿关节炎患者中,于基线及第4、16、28周定量肿瘤坏死因子(TNF),比较其动态变化与既往阿达木单抗数据。结果显示第4周TNF浓度与基线甲氨蝶呤(MTX)使用或28周缓解无关,中位TNF从基线<112 pg/ml升至第4周548 pg/ml后保持稳定。结论提示MTX对循环TNF浓度无直接影响。

要点

  • 依那西普治疗中循环TNF浓度与MTX使用无关联。
  • 第4周TNF浓度与28周缓解状态无关。
  • 阿达木单抗中早期低TNF与未用MTX的关联可能源于抗药抗体形成。

核心结论

  • 在依那西普治疗的类风湿关节炎患者中,循环TNF浓度与MTX使用无关,提示MTX对循环TNF无直接影响。

研究设计与样本

  • 研究连续纳入186例接受依那西普治疗的类风湿关节炎患者,在基线及第4、16、28周定量TNF,并与既往发表的阿达木单抗数据比较动态变化。

主要发现

  • 第4周TNF浓度与基线MTX使用或28周缓解无关联。
  • 中位(四分位距)TNF从基线<112(<112-<112)pg/ml升至第4周548(344-688)pg/ml,第16周为598(442-756)pg/ml,第28周为568(444-755)pg/ml。

临床怎么用

  • 依那西普治疗中无需因MTX使用状态而预期循环TNF浓度的差异。
  • 阿达木单抗治疗中早期低TNF与未用MTX的关联更可能反映抗药抗体形成而非MTX对TNF的直接抑制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recently, we demonstrated that early low concentrations of circulating, adalimumab-bound TNF in RA patients treated with adalimumab was associated with future anti-drug antibody formation. Furthermore, low TNF was associated with less frequent baseline MTX use. This is remarkable, because of the anti-inflammatory effects of MTX and a potential inhibiting effect on cytokine production. We hypothesized an indirect effect of non-MTX use on low TNF concentrations via immunogenicity. To investigate the effect of MTX on TNF concentrations independent of anti-drug antibody formation, we measured TNF in RA patients treated with etanercept, a drug with low immunogenicity. METHODS: TNF was quantified in 186 consecutive etanercept-treated RA patients at baseline and at weeks 4, 16 and 28. The dynamics of TNF during etanercept treatment were compared with dynamics recently published for adalimumab. RESULTS: We demonstrated that TNF concentrations at week 4 did not associate with baseline MTX or remission after 28 weeks. Furthermore, median (interquartile range) TNF increased from <112 (<112-<112) pg/ml at baseline to 548 (344-688) pg/ml at week 4 and remained stable at week 16 and 28 [598 (442-756) and 568 (444-755) pg/ml, respectively]. CONCLUSION: Circulating TNF did not associate with MTX usage in etanercept-treated patients. This implies that MTX does not have a direct effect on TNF concentrations in circulation and that the association between early low TNF and non-use of MTX for adalimumab is thus most likely due to anti-drug antibody formation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Berkhout LC, l'Ami MJ, Krieckaert CLM, et al. The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients. Rheumatology (Oxford). 2020. PMID: 31691828. doi:10.1093/rheumatology/kez513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。